Skip to Main Content

Author Details

Martin E Gleave
University of British Columbia
1987
636
107
PMIDPaper TitleJournal TitlePublished Year
37676819Molecular features of prostate cancer after neoadjuvant therapy in the phase 3 CALGB 90203 trial.J Natl Cancer Inst2024
36343223Dietary Patterns and Risk of Gleason Grade Progression among Men on Active Surveillance for Prostate Cancer: Results from the Canary Prostate Active Surveillance Study.Nutr Cancer2023
37800655Semaphorin 3C promotes de novo steroidogenesis in prostate cancer cells.Endocr Relat Cancer2023
37425866RNF185 control of COL3A1 expression limits prostate cancer migration and metastatic potential.bioRxiv2023
37259473A randomized controlled trial investigating rectus sheath catheters following radical cystectomy.BJU Int2023
37289025The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer.Cancer Res2023
37452083Influence of ADT on B7-H3 expression during CRPC progression from hormone-naïve prostate cancer.Cancer Gene Ther2023
37343766Artificial Intelligence-Based PTEN Loss Assessment as an Early Predictor of Prostate Cancer Metastasis After Surgery: A Multicenter Retrospective Study.Mod Pathol2023
37443749Dependency of Tamoxifen Sensitive and Resistant ER<sup>+</sup> Breast Cancer Cells on Semaphorin 3C (SEMA3C) for Growth.Cells2023
37003085Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022.Eur J Cancer2023
37068147A phase 1 study of an injectable lidocaine paste for spermatic cord block in men with chronic scrotal content pain.Can Urol Assoc J2023
36611121Chaperone-mediated autophagy promotes PCa survival during ARPI through selective proteome remodeling.Oncogene2023
36535377Dynamic phase separation of the androgen receptor and its coactivators key to regulate gene expression.Nucleic Acids Res2023
36932416Outcome of patients with biochemical recurrence of prostate cancer after PSMA PET/CT-directed radiotherapy or surgery without systemic therapy.Cancer Imaging2023
36494221Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022.Eur Urol2023
36727462SMAD3 promotes expression and activity of the androgen receptor in prostate cancer.Nucleic Acids Res2023
36596844Novel inhibition of AKR1C3 and androgen receptor axis by PTUPB synergizes enzalutamide treatment in advanced prostate cancer.Oncogene2023
35965411DDX5 mRNA-targeting antisense oligonucleotide as a new promising therapeutic in combating castration-resistant prostate cancer.Mol Ther2023
36343786UGT2B28 accelerates prostate cancer progression through stabilization of the endocytic adaptor protein HIP1 regulating AR and EGFR pathways.Cancer Lett2023
34711954Menin inhibition suppresses castration-resistant prostate cancer and enhances chemosensitivity.Oncogene2022
35440417Corrigendum to "What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021" [Eur Urol 82(1):6-11].Eur Urol2022
35641398First-line Systemic Treatment of Recurrent Prostate Cancer After Primary or Salvage Local Therapy: A Systematic Review of the Literature.Eur Urol Oncol2022
35467778Germline mutations in penetrant cancer predisposition genes are rare in men with prostate cancer selecting active surveillance.Cancer Med2022
35830553Impact of Prostate Health Index Results for Prediction of Biopsy Grade Reclassification During Active Surveillance.J Urol2022
35450732Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021.Eur Urol2022
35859180Deep whole-genome ctDNA chronology of treatment-resistant prostate cancer.Nature2022
36109521Transcriptional profiling of matched patient biopsies clarifies molecular determinants of enzalutamide-induced lineage plasticity.Nat Commun2022
35963852Reformation of the chondroitin sulfate glycocalyx enables progression of AR-independent prostate cancer.Nat Commun2022
35985981Erratum to "Phase 3 Randomized Controlled Trial of Androgen Deprivation Therapy with or Without Docetaxel in High-risk Biochemically Recurrent Prostate Cancer After Surgery (TAX3503)" [Eur Urol Oncol 2021;4:543-52].Eur Urol Oncol2022
363785722022 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: Management of castration-resistant prostate cancer (CRPC).Can Urol Assoc J2022
36251389The 5-Hydroxymethylcytosine Landscape of Prostate Cancer.Cancer Res2022
35014179THEM6-mediated reprogramming of lipid metabolism supports treatment resistance in prostate cancer.EMBO Mol Med2022
34854745Evaluating the Outcomes of Active Surveillance in Grade Group 2 Prostate Cancer: Prospective Results from the Canary PASS Cohort.J Urol2022
35218723The functions of clusterin in renal mesenchymal stromal cells: Promotion of cell growth and regulation of macrophage activation.Exp Cell Res2022
34939643Regulation of AR mRNA translation in response to acute AR pathway inhibition.Nucleic Acids Res2022
35176252Development and validation of a quantitative reactive stroma biomarker (qRS) for prostate cancer prognosis.Hum Pathol2022
35145197Analysis of separate training and validation radical prostatectomy cohorts identifies 0.25â¿¿mm diameter as an optimal definition for "large" cribriform prostatic adenocarcinoma.Mod Pathol2022
35082166Modeling Androgen Deprivation Therapy-Induced Prostate Cancer Dormancy and Its Clinical Implications.Mol Cancer Res2022
34516660Treatment in the absence of disease reclassification among men on active surveillance for prostate cancer.Cancer2022
32935392Clusterin regulates macrophage expansion, polarization and phagocytic activity in response to inflammation in the kidneys.Immunol Cell Biol2021
37145399Effect of Diagnostic Biopsy Practice Location on Grade/Volume Reclassification in Active Surveillance for Prostate Cancer: A Multicenter Analysis from the Canary PASS Cohort.Urol Pract2021
33598437Discovery of New Catalytic Topoisomerase II Inhibitors for Anticancer Therapeutics.Front Oncol2021
33542074Emergence of Enzalutamide Resistance in Prostate Cancer is Associated with BCL-2 and IKKB Dependencies.Clin Cancer Res2021
33709547Androgen receptor (AR) antagonism triggers acute succinate-mediated adaptive responses to reactivate AR signaling.EMBO Mol Med2021
33750801A noncanonical AR addiction drives enzalutamide resistance in prostate cancer.Nat Commun2021
335563132021 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: Management of castration-resistant prostate cancer (CRPC).Can Urol Assoc J2021
33801338Development of Novel Inhibitors Targeting the D-Box of the DNA Binding Domain of Androgen Receptor.Int J Mol Sci2021
33497248Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer: ASCO Guideline Update.J Clin Oncol2021
34934057The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer.Nat Commun2021
34385241A phase 3 randomised study of enzalutamide plus leuprolide and enzalutamide monotherapy in high-risk non-metastatic hormone-sensitive prostate cancer with rising PSA after local therapy: EMBARK study design.BMJ Open2021
  • 1 - 50 of 636

Recommended Authors

Wei Yuan
The Institute for Cancer Research
Career Start Year 2015
Number of shared co-authors 36
Richard J Rebello
University of Melbourne
Career Start Year 2015
Number of shared co-authors 10
Yuliang Wang
The Chinese University of Hong Kong
Career Start Year 2014
Number of shared co-authors 10
Pedro Isaacsson Velho
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins
Career Start Year 2013
Number of shared co-authors 20
Shuai Gao
Center for Personalized Cancer Therapy, University of Massachusetts Boston
Career Start Year 2012
Number of shared co-authors 28
Alec Paschalis
The Institute for Cancer Research
Career Start Year 2009
Number of shared co-authors 9
Susana Miranda
The Institute of Cancer Research
Career Start Year 2008
Number of shared co-authors 52
Mitchell G Lawrence
Biomedicine Discovery Institute, Monash University
Career Start Year 2005
Number of shared co-authors 15
Alok K Tewari
Dana-Farber Cancer Institute, Harvard Medical School
Career Start Year 2005
Number of shared co-authors 14
Roberta Ferraldeschi
Astex Pharmaceuticals
Career Start Year 2004
Number of shared co-authors 50
Channing J Paller
Johns Hopkins University School of Medicine
Career Start Year 2004
Number of shared co-authors 35
Thorsten Schlomm
Charite - University Hospital Berlin
Career Start Year 2004
Number of shared co-authors 39
Mark C Markowski
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Career Start Year 2001
Number of shared co-authors 21
Sooryanarayana Varambally
University of Alabama at Birmingham, USA O'Neal Comprehensive Cancer Center
Career Start Year 2001
Number of shared co-authors 27
Renea A Taylor
Peter MacCallum Cancer Centre
Career Start Year 1999
Number of shared co-authors 22
Hayley C Whitaker
University College London
Career Start Year 1999
Number of shared co-authors 25
Danny Vesprini
University of Toronto, Canada Odette Cancer Centre
Career Start Year 1998
Number of shared co-authors 32
J??rn Kamradt
Clinic of Urology and Pediatric Urology, University of Saarland
Career Start Year 1996
Number of shared co-authors 0
Simeng Suy
MedStar Georgetown University Hospital
Career Start Year 1996
Number of shared co-authors 10
Stanley K Liu
Odette Cancer Centre, University of Toronto
Career Start Year 1995
Number of shared co-authors 31
David I Quinn
USC Norris Comprehensive Cancer Center
Career Start Year 1993
Number of shared co-authors 37
Penny Flohr
The Institute of Cancer Research
Career Start Year 1993
Number of shared co-authors 58
Marshall Scott Lucia
University of Colorado School of Medicine
Career Start Year 1991
Number of shared co-authors 18
Guido Jenster
Erasmus University Medical Center
Career Start Year 1990
Number of shared co-authors 57
Gyorgy Petrovics
Henry Jackson Foundation for the Advancement of Military Medicine (HJF)
Career Start Year 1990
Number of shared co-authors 32
Adrie van Bokhoven
University of Colorado Anschutz Medical Campus
Career Start Year 1988
Number of shared co-authors 6
Freddie C Hamdy
University of Oxford
Career Start Year 1987
Number of shared co-authors 64
Tapio Visakorpi
Prostate Cancer Research Center, Tampere University and Tays Cancer Center
Career Start Year 1987
Number of shared co-authors 59
Nora M Navone
MD Anderson Cancer Center
Career Start Year 1987
Number of shared co-authors 30
Alan W Partin
The Brady Urological Institute, Johns Hopkins University School of Medicine
Career Start Year 1987
Number of shared co-authors 64

Collaborators

Ladan Fazli
University of British Columbia
Co-authored papers 179
Kim N Chi
University of British Columbia
Co-authored papers 72
Amina Zoubeidi
University of British Columbia
Co-authored papers 61
Yuzhuo Wang
University of British Columbia
Co-authored papers 51
Colin C Collins
University of British Columbia
Co-authored papers 47
Peter S Nelson
Fred Hutchinson Cancer Center
Co-authored papers 42
Antonio Hurtado-Coll
University of British Columbia
Co-authored papers 39
Daniel W Lin
Co-authored papers 37
Alexander W Wyatt
University of British Columbia
Co-authored papers 36
Fred Saad
University of Montreal Health Center
Co-authored papers 34
Ian M Thompson
CHRISTUS Santa Rosa Hospital-Medical Center
Co-authored papers 32
Himisha Beltran
Dana-Farber Cancer Institute
Co-authored papers 30
Eric J Small
University of California san francisco
Co-authored papers 28
Christopher P Evans
University of California Davis
Co-authored papers 27
Dong Lin
Fujian Medical University Cancer Hospital and Fujian Cancer Hospital
Co-authored papers 26
Tomasz M Beer
OHSU Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 25
Felix Y Feng
UCSF Medical Center-Mount Zion
Co-authored papers 25
Hui Xue
Agricultural Genomics Institute at Shenzhen, Chinese Academy of Agricultural Sciences
Co-authored papers 23
Neil E Fleshner
University of Toronto
Co-authored papers 20
Robert H Bell
University of British Columbia
Co-authored papers 20
Robert E Reiter
David Geffen School of Medicine at university of california los angeles
Co-authored papers 19
Rahul Aggarwal
University of California San Francisco
Co-authored papers 19
Lawrence D True
University of Washington School of Medicine
Co-authored papers 19
Jiaoti Huang
Duke University School of Medicine
Co-authored papers 19
Fan Mo
Institute of Stem Cell and Regeneration, Chinese Academy of Sciences
Co-authored papers 18
Joshi J Alumkal
Rogel Cancer Center, University of Michigan ann arbor
Co-authored papers 18
Mark A Rubin
University of Bern
Co-authored papers 18
Matthew B Rettig
David Geffen School of Medicine, University of California los angeles
Co-authored papers 16
Todd M Morgan
University of Michigan ann arbor
Co-authored papers 16
Matti Annala
University of British Columbia
Co-authored papers 15
Release 1.2